Scarica l'app Stockscreener
72.92
0.08%
0.06
Dopo l'orario di chiusura:
72.92
Precedente Chiudi:
$72.86
Aprire:
$72.81
Volume 24 ore:
3.69M
Relative Volume:
1.67
Capitalizzazione di mercato:
$11.26B
Reddito:
$10.73M
Utile/perdita netta:
$-455.74M
Rapporto P/E:
-20.50
EPS:
-3.5569
Flusso di cassa netto:
$-502.70M
1 W Prestazione:
+0.07%
1M Prestazione:
+0.44%
6M Prestazione:
+57.32%
1 anno Prestazione:
+134.32%
Intervallo 1D:
$72.81
$73.05
Intervallo di 1 settimana:
$72.73
$73.05
Portata 52W:
$21.51
$73.06
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.92 | 11.26B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.67 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Roth Capital | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential Amidst 434% Revenue Surge - DirectorsTalk Interviews
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders - Investing News Network
Avidity Biosciences Advances Toward Novartis Merger Completion - TipRanks
Avidity Biosciences to adjourn Feb 23 special meeting; Distribution expected Feb 26, Merger close Feb 27 - TradingView
Avidity postpones stockholder meeting, sets merger dates - Investing.com
Biotech delays key vote as Atrium stock distribution, Novartis merger approach - Stock Titan
Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus
Fiera Capital Corp Has $52.39 Million Position in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences, Inc. $RNA Shares Acquired by Envestnet Asset Management Inc. - MarketBeat
Aberdeen Group plc Buys 25,000 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity’s myotonic dystrophy drug shows promising results in trial - Investing.com Australia
Readystate Asset Management LP Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
HC Wainwright & Co. Downgrades Avidity Biosciences (RNA) - MSN
Assetmark Inc. Buys 21,507 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (RNA) to Release Earnings on Thursday - MarketBeat
Avidity Biosciences Reports Del-desiran Clinical Trial Results - Intellectia AI
Avidity’s myotonic dystrophy drug shows promising results in trial By Investing.com - Investing.com South Africa
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - Finviz
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PR Newswire
Avidity Biosciences reports data from DMD treatment trials - MSN
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential In RNA Therapeutics - DirectorsTalk Interviews
Avidity Biosciences Acquired by Novartis for $72 per Share - Intellectia AI
Allianz Asset Management GmbH Invests $632,000 in Avidity Biosciences, Inc. $RNA - MarketBeat
What drives Avidity Biosciences Inc.’s stock price2025 Dividend Review & Daily Profit Maximizing Tips - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
Does Avidity Biosciences Inc. have strong EBITDA marginsJuly 2025 Trends & Free High Return Stock Watch Alerts - mfd.ru
Is Avidity Biosciences Inc. stock near bottom after declineProduct Launch & Detailed Earnings Play Alerts - mfd.ru
Why Avidity Biosciences Inc. stock is recommended by analystsJuly 2025 Chart Watch & Smart Investment Allocation Tips - mfd.ru
Volume Report: How does Avidity Biosciences Inc compare to its peersAnalyst Downgrade & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Avidity Biosciences, Inc. $RNA Shares Acquired by Candriam S.C.A. - MarketBeat
Avidity Biosciences prices $600M stock offering - MSN
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Avidity Biosciences (RNA) - The Globe and Mail
(RNA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Key facts: JPMorgan raises concerns on Novartis outlook; Novartis to acquire Avidity - TradingView
Avidity Biosciences Announces Expected Record Date for Spin-Off - TradingView
Avidity Biosciences stock hits all-time high at 72.74 USD By Investing.com - Investing.com Australia
Avidity Biosciences receives FTC clearance for Novartis merger - MSN
Novartis (NVS) Acquisition of Avidity Biosciences Moves Forward - GuruFocus
Avidity Biosciences Sets February 15, 2026 as Record Date for Planned Spin-Off - geneonline.com
Avidity holders to get Atrium cardiology SpinCo shares in Novartis deal - stocktitan.net
Avidity Biosciences says record date set for February 12, 2026 for spin-off - marketscreener.com
Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off - TradingView
Avidity Biosciences Announces Share Distribution for Spin-Off - Intellectia AI
Avidity Biosciences (NASDAQ:RNA) Hits New 12-Month HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at 72.74 USD - Investing.com
New York State Common Retirement Fund Purchases 120,365 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Atle Fund Management AB Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Avidity Biosciences Sets February Vote on $72-per-Share Novartis Takeover and Cardiology Spin-Off - The Globe and Mail
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avidity Biosciences Inc Azioni (RNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
2.25%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):